Analyst Price Targets — OPRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 1:26 pm | — | UBS | $10.00 | $4.80 | TheFly | OptimizeRx price target lowered to $10 from $11 at B. Riley |
| May 13, 2026 12:49 pm | — | Lake Street | $11.00 | $4.86 | TheFly | OptimizeRx price target lowered to $11 from $20 at Lake Street |
| May 13, 2026 11:30 am | — | Stephens | $7.00 | $6.34 | TheFly | OptimizeRx price target lowered to $7 from $10 at Stephens |
| May 13, 2026 10:37 am | — | Stifel Nicolaus | $14.00 | $6.34 | TheFly | OptimizeRx price target lowered to $14 from $17 at Stifel |
| March 6, 2026 11:51 am | David Grossman | Stifel Nicolaus | $17.00 | $6.80 | StreetInsider | OptimizeRX (OPRX) PT Lowered to $17 at Stifel After Flattish Q4 Revenue |
| October 10, 2025 10:54 am | — | UBS | $23.00 | $18.29 | TheFly | OptimizeRx price target raised to $23 from $20 at Citizens JMP |
| April 4, 2024 2:26 am | Constantine Davides | JMP Securities | $15.00 | $11.17 | StreetInsider | JMP Securities Starts OptimizeRX (OPRX) at Market Outperform, 'Comprehensive Biopharma Digital Marketing Platform' |
Latest News for OPRX
Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest
Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts
WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.
Powered by OptimizeRx's new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers Powered by OptimizeRx's new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OPRX.
U.S. House Trading
No House trades found for OPRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.